Hypolipidemics Global Market Report 2024

The hypolipidemics market size has grown steadily in recent years. It will grow from $28.65 billion in 2023 to $29.93 billion in 2024 at a compound annual growth rate (CAGR) of 4.5%. The growth observed in the historical period can be attributed to several factors, including the increasing prevalence of hyperlipidemia, shifts in lifestyle choices, a growing aging population, heightened awareness and screening for lipid disorders, and the dominant use of statins as a common treatment approach. These factors collectively contributed to the growth of the hypolipidemic drug market in the past.

The hypolipidemics market size is expected to see steady growth in the next few years. It will grow to $34.93 billion in 2028 at a compound annual growth rate (CAGR) of 3.9%. The anticipated growth in the forecast period can be attributed to several factors, including the adoption of personalized medicine, the expansion of the patient pool, increased market opportunities in emerging economies, government initiatives to address lipid disorders, and the development of combination therapies. Furthermore, significant trends expected in the forecast period include a shift from managing LDL to non-HDL cholesterol, the integration of digital health and telemedicine, market consolidation and heightened competition, and a growing emphasis on patient-centric approaches in the hypolipidemic drug market.

Changes in dietary habits and lifestyle choices have been significant drivers in the growth of the hypolipidemic drugs market. Unhealthy food consumption, increased smoking, and alcohol intake have resulted in higher cholesterol levels in individuals. The World Health Organization's 2021 data indicates that cardiovascular diseases (CVDs) are a primary cause of global mortality, claiming approximately 17.9 million lives annually. The escalating levels of cholesterol due to lifestyle changes have led to an increased demand for hypolipidemic drugs as they aid in reducing cholesterol levels.

The primary product categories of hypolipidemic drugs include cholic acid regulators, HMG-CoA reductase inhibitors, adenylate cyclase inhibitors, nicotinic acid drugs, and various other types. HMG-CoA reductase inhibitors, in particular, are lipid-lowering medications widely employed for both primary and secondary prevention of coronary heart disease. These drugs are used and distributed through hospitals, clinics, pharmacies, and cardiology centers. Various drug types within this category include statins, bile acid sequestrants, cholesterol absorption inhibitors, PCSK9 inhibitors, and other formulations.

The hypolipidemic drugs market research report is one of a series of new reports that provides hypolipidemic drugs market statistics, including hypolipidemic drugs industry global market size, regional shares, competitors with a hypolipidemic drugs market share, detailed hypolipidemic drugs market segments, market trends and opportunities, and any further data you may need to thrive in the hypolipidemic drugs industry. This hypolipidemic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Rising occurrences of obesity are anticipated to propel the hypolipidemic drugs market's growth trajectory. Obesity, defined as having a body mass index (BMI) of 30 or higher, often results from taste modulators altering physiological responses to food, contributing to excessive weight gain. Hypolipidemic drugs play a role in addressing obesity by lowering heightened cholesterol levels, which can pose cardiovascular risks to individuals with excess body fat. The World Health Organization, as of March 2022, reported that an estimated 650 million adults, 340 million teenagers, and 39 million children are affected by obesity, with these numbers steadily increasing. The projection suggests that by 2025, approximately 167 million adults and children will be classified as overweight or obese. Therefore, the increasing prevalence of obesity is a driving force behind the hypolipidemic drug market.

The escalating use of biologics acts as a major deterrent hindering the growth of the hypolipidemic drugs market. Biologics, derived from living organisms, diverge from chemically synthesized drugs and have been gaining preference due to side effects associated with chemical drugs. This shift towards hypolipidemic biologic medicines has impacted the sales of traditional chemically synthesized hypolipidemic drugs, affecting their market growth. For example, according to Harvard Medical School, 10%-29% of individuals using hypolipidemic drugs, such as cholesterol-lowering statins, experience muscle aches and pains. The introduction of PCSK9 Inhibitors, a type of hypolipidemic biologic, has been in use since 2015 to reduce LDL cholesterol levels, exemplified by the FDA approval of Amgen's Repatha for hypolipidemia treatment.

Companies within this market sector are increasingly focusing on leveraging wearable data in clinical trials to enhance the speed, efficiency, and overall cost reduction of these trials. The continuous data collection from patients through wearable technologies can reduce the need for frequent site visits, leading to improved patient retention rates and overall efficiency in clinical trials. Wearables assist in addressing patient recruitment challenges, enabling real-time monitoring and data accuracy, thereby facilitating earlier decision-making during clinical trials. Pharmaceutical giants like Sanofi and Pfizer have already invested in wearable technology for treating hypolipidemia.

The approval process for hypolipidemic drugs by EU agencies generally takes 6 to 12 months and demands a single submission of the complete registration dossier, unlike the phased submissions accepted by the US FDA. While the FDA evaluates each technical section within six months, the process may be extended if queries or issues arise. However, simultaneous assessments of the technical sections require manufacturers to plan and identify time-consuming steps to estimate approval dates effectively. In the EU region, the licensing validity and application renewals add significant regulatory complexity, compelling manufacturers to communicate and plan effectively to minimize costs and reduce timelines.

Key companies in the hypolipidemic drugs market are directing their efforts towards introducing lipid-lowering medications like Brillo to gain a competitive advantage. Brillo is an oral lipid-lowering drug featuring bempedoic acid, a first-in-class compound designed to reduce low-density lipoprotein (LDL) cholesterol, a primary risk factor for cardiovascular diseases. In May 2022, Sun Pharmaceutical Industries Limited, an India-based pharmaceutical company, unveiled Brillo in India. This medication utilizes bempedoic acid, offering a unique mode of action distinct from existing lipid-lowering agents. Brillo is prescribed for individuals with genetically high cholesterol or confirmed heart disease, especially when cholesterol levels remain high despite lifestyle modifications and the highest acceptable statin doses.

Major companies operating in the hypolipidemics market include Abbott Laboratories Limited, Apotex Fermentation Inc., Biocon Limited, Cadila Healthcare Limited, Chunghwa Chem Syn& Biotech Co. Ltd., Concord Biotech Limited, Croda Europe Limited, Daiichi Sankyo Company Limited, Dr. Reddy’s Laboratories Ltd., DSM Sinochem Pharma India Pvt. Ltd., Hikal Chemicals Industries Limited, Ipca Laboratories Ltd., Lek Pharmaceuticals D.d, Lupin Limited, Merck Sharp & Dohme B.V, Mylan N.V, Nexchem Pharmaceutical Co. Ltd., Olon S.p.A, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Zhejiang Jiangbei Pharma Co. Ltd., Moehs Iberica S.L. ES, Pfizer Inc., Recordati S.p.A., AstraZeneca Plc, Amgen Plc, Daiichi Sankyo Company Limited, Kowa Company Ltd., Sanofi-Aventis, Novartis AG, Viatris Inc., Pfizer Inc., GlaxoSmithKline plc, Cipla Limited, Torrent Pharmaceuticals Ltd., Zydus Lifesciences Limited, Wockhardt Limited, Alembic Pharmaceuticals Limited, Jubilant Life Sciences Limited, Hetero Drugs Limited, Ind-Swift Laboratories Ltd., Intas Pharmaceuticals Ltd., Unichem Laboratories Ltd.

North America was the largest region in the hypolipidemic drugs market in 2023. The Middle East is expected to be the fastest-growing region in the hypolipidemic drugs market during the forecast period. The regions covered in the hypolipidemics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the hypolipidemics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The hypolipidemic drugs market consists of sales of cholesterol absorption inhibitors, bile acid sequestrants, and fibric acid derivatives. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.